Forsberg; Goran

Patent Applications and Registrations

Patent applications and USPTO patent grants for Forsberg; Goran.The latest application filed is for "anti-il1rap antibody compositions".

Company Profile

0.9.11

Forsberg; Goran - Eslov SE
FORSBERG; Goran - Karlstad SE
Forsberg; Goran - Bollnas SE
FORSBERG; GORAN - ESLOEV SE
Forsberg; Goran - Malmo SE
Forsberg; Goran - Lund SE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-IL1RAP Antibody Compositions App 20220267454 - Forsberg; Goran ; et al.	2022-08-25
Feeder Tube And Method Relating To A Feeder Tube App 20160052721 - FORSBERG; Goran	2016-02-25
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent Grant 8,293,243 - Hedlund , et al. October 23, 2	2012-10-23
Crushing plant and method for controlling the same Grant 8,172,167 - Hedin , et al. May 8, 2	2012-05-08
Treatment Of Hyperproliferative Disease With Superantigens In Combination With Another Anticancer Agent App 20100303836 - HEDLUND; GUNNAR ; et al.	2010-12-02
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent Grant 7,763,253 - Hedlund , et al. July 27, 2	2010-07-27
Crushing Plant And Method For Controlling The Same App 20100181396 - Hedin; Olle ; et al.	2010-07-22
Conjugates Between A Variant Staphylococcal Enterotoxin E Superantigen And A Targeting Antibody That Binds To A Cancer-associated Cell Surface Structure App 20100111978 - FORSBERG; GORAN ; et al.	2010-05-06
Methods for treating a subject having cancer by the administration of a conjugate between a variant staphylococcal entertoxin E superantigen and an antibody that binds to the 5T4 antigen Grant 7,615,225 - Forsberg , et al. November 10, 2	2009-11-10
Modified Chimeric superantigens and their use Grant 7,226,595 - Antonsson , et al. June 5, 2	2007-06-05
Novel engineered superantigen for human therapy App 20070082001 - Forsberg; Goran ; et al.	2007-04-12
Engineered superantigen for human therapy Grant 7,125,554 - Forsberg , et al. October 24, 2	2006-10-24
Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent App 20060057111 - Hedlund; Gunnar ; et al.	2006-03-16
Cytolysis of target cells by superantigen conjugates inducing T-cell activation Grant 6,962,694 - Soegaard , et al. November 8, 2	2005-11-08
Cytolysis of target cells by superantigen conjugates inducing T-cell activation App 20050226885 - Soegaard, Morten ; et al.	2005-10-13
Feeder tube for bulk product Grant 6,722,491 - Forsberg April 20, 2	2004-04-20
Modified chimeric superantigens and their use App 20030092894 - Antonsson, Per ; et al.	2003-05-15
Novel engineered superantigen for human therapy App 20030039655 - Forsberg, Goran ; et al.	2003-02-27
Modified/chimeric superantigens and their use Grant 6,514,498 - Antonsson , et al. February 4, 2	2003-02-04
Feeder tube for bulk product App 20020170804 - Forsberg, Goran	2002-11-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.